Header

UZH-Logo

Maintenance Infos

Epilepsy and cannabidiol: a guide to treatment


Abstract

The growing interest in cannabidiol (CBD), specifically a pure form of CBD, as a treatment for epilepsy, among other conditions, is reflected in recent changes in legislation in some countries. Although there has been much speculation about the therapeutic value of cannabis-based products as an anti-seizure treatment for some time, it is only within the last two years that Class I evidence has been available for a pure form of CBD, based on placebo-controlled RCTs for patients with Lennox-Gastaut syndrome and Dravet syndrome. However, just as we are beginning to understand the significance of CBD as a treatment for epilepsy, in recent years, a broad spectrum of products advertised to contain CBD has emerged on the market. The effects of these products are fundamentally dependent on the purity, preparation, and concentration of CBD and other components, and consensus and standardisation are severely lacking regarding their preparation, composition, usage and effectiveness. This review aims to provide information to neurologists and epileptologists on the therapeutic value of CBD products, principally a purified form, in routine practice for patients with intractable epilepsy.

Abstract

The growing interest in cannabidiol (CBD), specifically a pure form of CBD, as a treatment for epilepsy, among other conditions, is reflected in recent changes in legislation in some countries. Although there has been much speculation about the therapeutic value of cannabis-based products as an anti-seizure treatment for some time, it is only within the last two years that Class I evidence has been available for a pure form of CBD, based on placebo-controlled RCTs for patients with Lennox-Gastaut syndrome and Dravet syndrome. However, just as we are beginning to understand the significance of CBD as a treatment for epilepsy, in recent years, a broad spectrum of products advertised to contain CBD has emerged on the market. The effects of these products are fundamentally dependent on the purity, preparation, and concentration of CBD and other components, and consensus and standardisation are severely lacking regarding their preparation, composition, usage and effectiveness. This review aims to provide information to neurologists and epileptologists on the therapeutic value of CBD products, principally a purified form, in routine practice for patients with intractable epilepsy.

Statistics

Citations

Dimensions.ai Metrics
70 citations in Web of Science®
80 citations in Scopus®
Google Scholar™

Altmetrics

Downloads

1053 downloads since deposited on 25 Jan 2021
1044 downloads since 12 months
Detailed statistics

Additional indexing

Contributors:The Cannabinoids International Experts Panel, Collaborators
Item Type:Journal Article, refereed, further contribution
Communities & Collections:04 Faculty of Medicine > University Children's Hospital Zurich > Medical Clinic
Dewey Decimal Classification:610 Medicine & health
Scopus Subject Areas:Life Sciences > Neurology
Health Sciences > Neurology (clinical)
Language:English
Date:1 February 2020
Deposited On:25 Jan 2021 15:04
Last Modified:24 Jun 2024 01:44
Publisher:John Libbey Eurotext
ISSN:1294-9361
OA Status:Hybrid
Free access at:Publisher DOI. An embargo period may apply.
Publisher DOI:https://doi.org/10.1684/epd.2020.1141
Official URL:https://www.jle.com/fr/revues/epd/e-docs/epilepsy_and_cannabidiol_a_guide_to_treatment_316272/article.phtml
PubMed ID:32096470
  • Content: Published Version
  • Language: English
  • Licence: Creative Commons: Attribution-ShareAlike 4.0 International (CC BY-SA 4.0)